Abstract-Objectiues; To understand how commonly diminution of verbal repetition was a goal of treatmenl in patients with A.lzheimer disease (AD), how commonly that goal was achieved, whether goal attainment might be attributable to galaltaroine treatment, and whether change in verbal repetition is a marker of the overall treatment response. Mel,4odsi This is a secondary anaiysis of the Video-Imaging Synthesis of Treating Alzheimer's Disease study, a 4-month, 
Here, we investigated how commonJy diminution of verbal repetition was set as a treatment goal in VISTA, how comrnonly that goal was achieved, whether goal attainment might be attributable to galantamine treatrnent, and whether change in verbal repetition is a marker of the overall treatment Iesponse. Methods. Serting, instrurnent:t, and population. This is a sec ondary analysis ofthe VISTA trial, a 4-month, placebo-cootrol1ed, multicenter, Canadian, parallel-gtoup, randomized clinical tdal of galantamine.' The initial placebo-controlled phase was followed by a 4-month, openJabel phase, duriDg which the patients who were originally assigled to placebo were tteated with the active com The patient GAS facilitator also completeal the Clinician,s
Interview-Based In]pressiotr of Change-plus Caregiver Input (CIBIC-Pius),ri but was biind to all other study measuies. In tum, study physicians were bLind to lhe patient GAS process and to the CIBIC-Plus rating. Severa) additional (secondart) outcome measures were collectcd, inctuding the ADAS-CoC,1' the Disabitity Assessment for Dementia (DAD),r'and the Care-giving Burden Scale (CBS).G A11 outcomes were assessed at bas;line. GAS, CIBICPIus. and ADAS-Cog outcomes were followed bimonthly, whereas the DAD and CBS were followed up at 4 and 8 months.
. with Ine last oosprvation carried forwaro a" ,t,. "r;.r^-]"i".f. and obsprved .ase. as the s"conoa.1 ao,1ys,l. 1]";;;;i"'; pnofl to coDdu.l only ao observed casF aralysis to assess patjprrs who provided data at the scheduled evaluation p"*t".
-fil"" "i"" addressp< tnp .oncpro thal. jn ,. !eg"o"r",ir" disordpr. carrvioe IoIvarO tn. Iast oDsprvation can bias rhF r"sults in favor of OeOoli who orop our .arly d-e to side effecrs .ra ,f.." f,"r" f"". "pi".i, nity to decline.
Ethics. We believed that treatment in a carefully monitoreil, placcbo-controlled phase was erhically pennis.ible ior uo ro t6 week". wirh parienLs given 'hp opporrLrniry r" "
ii1.j..*.",qi pr_ tients and caregiverc provided written i"t"r*"a """"""i,
i"jiJ_ ing consent forvideo reco ing. Each instit"tio.r," n"""*"L nini* Committee and the Therapeutics produci Di;;;;;-a";;'H"e";jth Canada approved the protocol.
Role of the sporcor. This peer_reviewed, investigator-initiated trial was jointly funded by Janssen-Ortho Cr"_d.-?8dt;;;;; Canadian lnsrirurFs ol Healrh Rpseareh ,2Oi-,;r;r .;-DCi_ 49981). The sponsor provided all msdigs1i."" .ria''"i.t"ii"g p1*"-bos, cooducted on-site moDitoring, a"a g.tlrurua ""a "1e;3rrl".ily coded the case report forms. All data ar.e nefa t" tfr" F.i""i"r't Investigator (K.R.), who initiated aid ""p"*i""-a ;ii ;;;t;;". 
